Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus
出版年份 2021 全文链接
标题
Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus
作者
关键词
SARS CoV 2, Antibodies, Mouse models, Enzyme-linked immunoassays, Serum proteins, Vaccination and immunization, Antigenic variation, Vaccines
出版物
PLOS BIOLOGY
Volume 19, Issue 12, Pages e3001384
出版商
Public Library of Science (PLoS)
发表日期
2021-12-17
DOI
10.1371/journal.pbio.3001384
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Preliminary report of an outbreak of SARS-CoV-2 in mink and mink farmers associated with community spread, Denmark, June to November 2020
- (2021) Helle Daugaard Larsen et al. Eurosurveillance
- Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein
- (2021) Houriiyah Tegally et al. NATURE
- Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model
- (2021) Fatima Amanat et al. mBio
- Antibody evasion by the P.1 strain of SARS-CoV-2
- (2021) Wanwisa Dejnirattisai et al. CELL
- Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
- (2021) Venkata Viswanadh Edara et al. Cell Host & Microbe
- Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
- (2021) Shabir A. Madhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
- (2021) Nuno R. Faria et al. SCIENCE
- SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness
- (2021) Aziz Sheikh et al. LANCET
- Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients
- (2021) Juan Manuel Carreño et al. EBioMedicine
- A serological assay to detect SARS-CoV-2 seroconversion in humans
- (2020) Fatima Amanat et al. NATURE MEDICINE
- Convergent antibody responses to SARS-CoV-2 in convalescent individuals
- (2020) Davide F. Robbiani et al. NATURE
- A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
- (2020) Xiangyang Chi et al. SCIENCE
- Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
- (2020) Allison J. Greaney et al. Cell Host & Microbe
- Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate
- (2020) Weina Sun et al. EBioMedicine
- Broadly cross-reactive, non-neutralizing antibodies against the influenza B virus hemagglutinin demonstrate effector function dependent protection against lethal viral challenge in mice
- (2019) Guha Asthagiri Arunkumar et al. JOURNAL OF VIROLOGY
- Monoclonal Antibodies with Neutralizing Activity and Fc-Effector Functions against the Machupo Virus Glycoprotein
- (2019) Fatima Amanat et al. JOURNAL OF VIROLOGY
- Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection
- (2018) Erica Ollmann Saphire et al. CELL
- Antibody-mediated protection against Ebola virus
- (2018) Erica Ollmann Saphire et al. NATURE IMMUNOLOGY
- Vaccination with Adjuvanted Recombinant Neuraminidase Induces Broad Heterologous, but Not Heterosubtypic, Cross-Protection against Influenza Virus Infection in Mice
- (2015) Teddy John Wohlbold et al. mBio
- Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo
- (2014) David J DiLillo et al. NATURE MEDICINE
- Coronaviruses
- (2011) Mark R. Denison et al. RNA Biology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started